<?xml version='1.0' encoding='utf-8'?>
<document id="25803093"><sentence text="Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects."><entity charOffset="10-18" id="DDI-PubMed.25803093.s1.e0" text="rifampin" /><entity charOffset="46-55" id="DDI-PubMed.25803093.s1.e1" text="bosutinib" /><entity charOffset="72-80" id="DDI-PubMed.25803093.s1.e2" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.25803093.s1.e0" e2="DDI-PubMed.25803093.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25803093.s1.e0" e2="DDI-PubMed.25803093.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25803093.s1.e0" e2="DDI-PubMed.25803093.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25803093.s1.e1" e2="DDI-PubMed.25803093.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25803093.s1.e1" e2="DDI-PubMed.25803093.s1.e2" /></sentence><sentence text="Bosutinib is an orally bioavailable dual Src/Abl tyrosine kinase inhibitor and a CYP3A4 enzyme substrate"><entity charOffset="0-9" id="DDI-PubMed.25803093.s2.e0" text="Bosutinib" /><entity charOffset="49-57" id="DDI-PubMed.25803093.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.25803093.s2.e0" e2="DDI-PubMed.25803093.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25803093.s2.e0" e2="DDI-PubMed.25803093.s2.e1" /></sentence><sentence text=" This study assessed the safety, tolerability, and pharmacokinetics of bosutinib when coadministered with the CYP3A4 inducer rifampin in 24 healthy men"><entity charOffset="71-80" id="DDI-PubMed.25803093.s3.e0" text="bosutinib" /><entity charOffset="125-133" id="DDI-PubMed.25803093.s3.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.25803093.s3.e0" e2="DDI-PubMed.25803093.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25803093.s3.e0" e2="DDI-PubMed.25803093.s3.e1" /></sentence><sentence text="" /><sentence text="Subjects received single oral doses of bosutinib 500 mg (Days 1 and 14) and once-daily oral doses of rifampin 600 mg (Days 8-17); serial blood samples were analyzed"><entity charOffset="39-48" id="DDI-PubMed.25803093.s5.e0" text="bosutinib" /><entity charOffset="101-109" id="DDI-PubMed.25803093.s5.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.25803093.s5.e0" e2="DDI-PubMed.25803093.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25803093.s5.e0" e2="DDI-PubMed.25803093.s5.e1" /></sentence><sentence text="" /><sentence text="Bosutinib exposures were reduced following concomitant administration of rifampin vs"><entity charOffset="0-9" id="DDI-PubMed.25803093.s7.e0" text="Bosutinib" /><entity charOffset="73-81" id="DDI-PubMed.25803093.s7.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.25803093.s7.e0" e2="DDI-PubMed.25803093.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25803093.s7.e0" e2="DDI-PubMed.25803093.s7.e1" /></sentence><sentence text=" bosutinib alone, measured by peak plasma concentration (C(max); 112 vs"><entity charOffset="1-10" id="DDI-PubMed.25803093.s8.e0" text="bosutinib" /></sentence><sentence text=" 16" /><sentence text="0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs" /><sentence text=" 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs" /><sentence text=" 158 ng·h/mL; 94% reduction)" /><sentence text=" Median time to C(max) and mean half-life were shorter for bosutinib plus rifampin vs" /><sentence text=" single-agent bosutinib"><entity charOffset="14-23" id="DDI-PubMed.25803093.s14.e0" text="bosutinib" /></sentence><sentence text=" Oral clearance increased approximately 13-fold; the volume of distribution increased from 9560 to 72,900 L" /><sentence text=" Treatment-emergent adverse events appeared less frequently with bosutinib plus rifampin (59%) vs"><entity charOffset="65-74" id="DDI-PubMed.25803093.s16.e0" text="bosutinib" /><entity charOffset="80-88" id="DDI-PubMed.25803093.s16.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.25803093.s16.e0" e2="DDI-PubMed.25803093.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25803093.s16.e0" e2="DDI-PubMed.25803093.s16.e1" /></sentence><sentence text=" single-agent bosutinib (79%); diarrhea was reported in 11 (46%) vs"><entity charOffset="14-23" id="DDI-PubMed.25803093.s17.e0" text="bosutinib" /></sentence><sentence text=" 4 (18%) subjects, respectively" /><sentence text="" /><sentence text="Concomitant use of potent or moderate CYP3A inducers with bosutinib should be avoided because of the effects of drug-drug interaction observed between bosutinib and rifampin"><entity charOffset="58-67" id="DDI-PubMed.25803093.s20.e0" text="bosutinib" /><entity charOffset="151-160" id="DDI-PubMed.25803093.s20.e1" text="bosutinib" /><entity charOffset="165-173" id="DDI-PubMed.25803093.s20.e2" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.25803093.s20.e0" e2="DDI-PubMed.25803093.s20.e0" /><pair ddi="false" e1="DDI-PubMed.25803093.s20.e0" e2="DDI-PubMed.25803093.s20.e1" /><pair ddi="false" e1="DDI-PubMed.25803093.s20.e0" e2="DDI-PubMed.25803093.s20.e2" /><pair ddi="false" e1="DDI-PubMed.25803093.s20.e1" e2="DDI-PubMed.25803093.s20.e1" /><pair ddi="false" e1="DDI-PubMed.25803093.s20.e1" e2="DDI-PubMed.25803093.s20.e2" /></sentence><sentence text="" /></document>